JNJ Johnson & Johnson

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by the Board of Directors of Johnson & Johnson

NEW YORK--(BUSINESS WIRE)--

Levi & Korsinsky announces it has commenced an investigation of Johnson & Johnson (NYSE:JNJ) (“Johnson & Johnson” or the “Company”) concerning possible violations of federal securities laws.

On February 5, 2018, CNBC published an article alleging that “court proceedings could expose potentially damaging documents” related to certain Johnson & Johnson’s talc products. On this news, shares of Johnson & Johnson fell $7.29 per share or over 5%, to close at $130.39 on February 5, 2018. To obtain additional information, go to:

http://www.zlkdocs.com/JNJ-Info-Request-Form-6450

or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972.

Levi & Korsinsky is a national firm with offices in New York, California, Connecticut and Washington D.C. The firm’s attorneys have extensive expertise in prosecuting securities litigation involving financial fraud, representing investors throughout the nation in securities and shareholder lawsuits. Attorney advertising. Prior results do not guarantee similar outcomes.

EN
09/02/2018

Underlying

JNJJohnson & Johnson

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Johnson & Johnson

Free Trial
JNJ Johnson & Johns...

Johnson & Johnson: 1 director

A director at Johnson & Johnson sold 100,000 shares at 221.229USD and the significance rating of the trade was 75/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cle...

JNJ JOHNSON & JOHNSON
01/29/26 January 29, 2026 1 EN
JNJ Johnson & Johns...

Johnson & Johnson - September 2025 (LTM): Peer Snapshot

Compares key performance metrics against industry peers.

JNJ JOHNSON & JOHNSON
11/24/25 November 24, 2025 1 EN
Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke
EUR 43.03
SNYN SANOFI S.A. ADS
NOVA Novo Nordisk A/... ... (+11)

Vermilion Compass: Weekly Equity Strategy

Coasting as We Stalk for Buying Opportunity; Downgrading Discretionary to Underweight We had been near-term bullish on the S&P 500 (SPX) since our 4/22/25 Compass, however, we are officially downgrading our near-term outlook to neutral. The SPX, Nasdaq 100 (QQQ), and Russell 2000 (IWM) are breaking below their 50-day MAs and are also violating their multi-month uptrends, signaling a consolidation period is here. With that said, our intermediate-term outlook remains bullish (as of our 5/14/25 Co...

SNYN SANOFI S.A. ADS
NOVA NOVO NORDISK A/S ADS
MRK MERCK & CO. INC.
LLY ELI LILLY AND COMPANY
JNJ JOHNSON & JOHNSON
BMY BRISTOL-MYERS SQUIBB COMPANY
NVS.. NOVARTIS AG ADS
ABBV ABBVIE INC.
BAYA BAYER AG ADS
AZN ASTRAZENECA PLC ADS
GSK GSK PLC
11/19/25 November 19, 2025 1 EN
JNJ Johnson & Johns...

Johnson & Johnson: Key facts and statistics - LTM June 2025

A summary company profile, detailing Johnson & Johnson’s business operations and financial highlights.

JNJ JOHNSON & JOHNSON
10/22/25 October 22, 2025 1 EN
JNJ Johnson & Johns...

Moody's Ratings says J&J's Ortho separation will modestly reduce scale...

Moody's Ratings (Moody's) said that on 14 October, Johnson & Johnson ("J&J") announced that it intends to separate its Orthopaedics business into an independent company called DePuy Synthes. The separation of the Orthopaedics business, which is part of J&J's medical devices segment ("MedTech") will ...

JNJ JOHNSON & JOHNSON
10/14/25 October 14, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch